Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Dermatology Drugs in Phase III Clinical Development in SWITZERLAND

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Galderma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              Galderma Announces Results from Phase 2 Study of Investigational Therapy Nemolizumab for Moderate to Severe Prurigo Nodularis

              Contact the Supplier

              Lead Product(s): Nemolizumab

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2020

              Details:

              Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo.

              Novartis Pharmaceuticals Corporation

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urtica...

              Contact the Supplier

              Lead Product(s): Ligelizumab

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2020

              Details:

              LIGELIZUMAB (QGE031) more effective than XOLAIR® at inhibiting immunoglobulin E- pathway responsible for chronic spontaneous urticaria.

              PharmaCompass__DigitalAd